|Articles|September 1, 2016
- Pharmaceutical Executive-09-01-2016
- Volume 36
- Issue 9
Pharmaceutical Executive, September 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 9 years ago
Pharm Exec's Emerging Pharma Leaders 2016over 9 years ago
Emerging Leaders 2016: Lessons from the Front Benchover 9 years ago
Patient-Centered Strategies for Clinical Trials & Treatmentover 9 years ago
Rise of the Vox Populiover 9 years ago
Opioid Epidemic Prompts More Finger Pointing at Pharmaover 9 years ago
Country Report: France, Part IINewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
WHO Finalizes United States’ Withdrawal from Organization: Report
2
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
3
Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development
4
Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics
5